Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies
FDA's decision was supported by Ph......
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies
FDA's decision was supported by Ph......
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies
FDA's decision was supported by Ph......
SHANGHAI--(BUSINESS WIRE)--Robbyant, an embodied AI company within Ant Group, today announced the open-source release of LingBot-World 2.0 (Infinity). This interactive world model significantly upgrad......
